Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
66–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Newly initiated nintedanib during 10/01/2014 to 12/31/2018
Were at least 66 years old as of the date of their first nintedanib prescription claim (index date)
Qualified for Medicare based on age
Had at least 12 months (365 days) of continuous enrollment in Medicare Parts A, B and D before (baseline period) and 12 months (360 days) after the index date (follow-up period)
Had at least one inpatient or two outpatient claims (\>14 days apart) with a diagnosis code for Idiopathic Pulmonary Fibrosis (IPF) during the baseline period
You may not be if
Had any history of pirfenidone or nintedanib use during the baseline period
Had any history of lung transplant during the baseline, index date or follow-up periods
Had any claims for skilled nursing facility, long-term care facility or hospice during the baseline, index date or follow-up period
Had evidence during the baseline period of any of the following conditions: lung cancer, autoimmune, or connective tissue diseases (i.e. rheumatoid arthritis (RA), sarcoidosis, systemic lupus erythematosus (SLE), dermatopolymyositis, systemic sclerosis, Sjogren's, and mixed connective tissue disease (CTD)) during the baseline period
Had dual eligibility of Medicare and Medicaid
Had history of using pirfenidone at the same time with nintedanib during follow-up